A Comparative Study o fIntavenous Methylprednisolone Dosage for Treatment of Children with Acute Idiopathic Thrombocytopenic Purpura.
- Author:
Eun Ju SHIN
1
;
Yeong Jae SONG
;
Woo Yeong CHUNG
;
Tae Gyu HWANG
;
Soon Yong LEE
Author Information
1. Department of Pediatrics, Inje University College of Medicine, Pusan Paik Hospital, Pusan, Korea.
- Publication Type:Comparative Study ; Original Article
- Keywords:
Idiopathic thrombocytopenic purpura;
Methylprednisolone
- MeSH:
Child*;
Diagnosis;
Headache;
Humans;
Methylprednisolone*;
Platelet Count;
Purpura, Thrombocytopenic, Idiopathic*
- From:Journal of the Korean Pediatric Society
1995;38(4):513-519
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: It is well known that use of intranenous methylprednisolone(IVMP)for the patients with idiopathic thrombocytopenic purpura(ITP) is not only as effective as use of intravenous gammaglobulin to mincrease platelets quickly, but also the former is less expensive than the latter. As the adequate dosage of IVMP has not been fully elucidated, we have tried to determine it. METHODS: The subjects were 35 childhood patients below 15 years of age, who were diagnosed with ITP for the first time and whose platelet count was less than 20,000/mm(3) at diagnosis. We divided them into three groups : Group A included 8 cases with IVMP dosage of 5mg/kg/day, Group B included 9 patients with IVMP dosage of 10mg/kg/day, and group C included 18 patients with IVMP dosage of 20mg/kg/day. We checked the platelet count every day after IVMP administration daily for 5 days and also observed for side effects if any. RESULTS: After IVMP administration, we obseved increasing tendency of platelets in all three groups, of which group C was more rapid and higher in increasing platelets than the other groups(p<0.05). After IVMP therapy for 5 days, cases with platelets>20,000/mm(3) were 6(75%) in group A, 7(78%) in group B, and 18(100%) in group C. Cases with platelets >50,000/mm(3) were 5(63%), 6(67%), 17(94%) in groups A, B, C, respectively, and cases with platelets> 100,000/mm(3) were 3(38%), 5(56%), 14(78%), in group A, B, C, respectively. And there were no remarkable side effects except a case of transient hypertensive headache in group C. CONCLUSIONS: We concluded that the effectiveness of IVMP therapy for increasing platelets was more rapid and higher in group C than in group A or B, and side effect was minimal.
